Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE